This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Health Winners & Losers

Mergers, earnings and an IPO jolted a few biotech stocks Tuesday.

Medical device company E-Z-EM (EZEM) said Tuesday that it agreed to be bought by Bracco Diagnostics for $241 million, or $21 a share, pending shareholder vote. The price is a 32% premium over the 10-day average closing price as of Oct. 29.

Shares rose $4.08, or 24.9%, to $20.50.

Nycomed also said it will buy dermatologic company Bradley Pharmaceuticals (BDY) for $346 million. The bid is for $20 a share, a $4 premium over Monday's closing price of $16. Bradley's board approved the merger, which is now subject to shareholder vote. Shares added $3.80, or 23.8%, to $19.80.

On the earnings front, Sepracor (SEPR) reported a third-quarter profit of $42.9 million, or 37 cents a share, compared to $64.4 million, or 56 cents a share, a year ago. It reported revenue of $283.9 million, a 1.9% decrease from $289.3 million in the year-ago quarter. Analysts surveyed by Thomson Financial had expected 26 cents a share on revenue of $289 million.

The company also said it will cut 300 jobs, resulting in a reduction in sales and marketing expenses of $90 million to $100 million. Shares climbed $3.88, or 16.9%, to $26.90.

Teva Pharmaceuticals (TEVA - Get Report) reported third-quarter earnings of $525 million, or 64 cents a share, vs. a profit of $606 million, or 74 cents a share, in the year-ago quarter. Revenue rose to $2.37 billion from $2.29 billion in 2006. Analysts polled by Thomson Financial expected profit of 63 cents per share on revenue of $2.41 billion.

The company also said CFO Dan Suesskind, who worked at the company for 31 years, will retire in the middle of next year. He'll be replaced by Eyal Desheh, chief financial officer of Check Point Software Technologies in Tel Aviv. Teva shares gave up 83 cents, or 1.9% to $43.66.

Teva is a component of the Amex Pharmaceutical Index, which edged lower 0.05, or 0.01%, to 348.66.

Monday after close, Nastech (NSTK) reported a loss of $16.5 million, or 66 cents a share, vs. a loss of $7.8 million, or 36 cents a share, in the year-ago quarter. Revenue fell 66 percent to $1.9 million from $5.5 million in the year-earlier period. Analysts polled by Thomson Financial expected a loss of 44 cents a share. Shares fell $1.80, or 12.1%, to $13.05.

Viropharm (VPHM) said it earned $21.3 million, or 26 cents a share, vs. $23.3 million, or 33 cents a share, in the comparable 2006 quarter. Revenue fell to $50.9 million from $55.2 million. Analysts surveyed by Thomson Financial had expected 27 cents a share, on revenue of $52 million.

Shares fell 67 cents, or 7.2%, to $8.77.

Elsewhere, Genoptix (GXDX) soared 56.4% after its IPO, which priced 5 million shares at $17 a pop, along with a 750,000-share underwriters' option. Shares of the San Diego-based diagnostic services provider were up $9.59 to $26.59.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
VPHM $49.96 -0.02%
TEVA $53.83 -0.68%
AAPL $94.19 -1.04%
FB $118.06 0.54%
GOOG $695.70 0.48%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs